ग्लेनमार्क फार्मास्युटिकल्स शेअर किंमत

अर्निंग्स कॉलची ट्रान्सक्रिप्ट

• बीएसई इंडिया
• 1 दिवस 20 तासांपूर्वी

Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 2026

• बीएसई इंडिया
• 3 दिवस 20 तासांपूर्वी

<h3><span style="font-size:16px;"><strong>फार्मास्युटिकल्स कंपनी ग्लेनमार्क फार्मास्युटिकल्सने Q1FY27 परिणाम घोषित केले</strong></span></h3><p _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">एकत्रित फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c3377174747="">Total Revenue from Operations: The consolidated revenue for Q1FY27 stood at Rs 40,184.83 million, representing a growth of 23.10% YoY compared to Rs 32,644.40 million in Q1FY26 and a 6.57% increase QoQ from Rs 37,705.86 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Income: The company reported a total income of Rs 40,842.47 million in Q1FY27, up by 24.11% YoY from Rs 32,908.82 million in Q1FY26 and an increase of 3.15% QoQ from Rs 39,596.69 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit After Tax (Attributable to Owners): Profit for Q1FY27 surged significantly by 930.33% YoY to Rs 4,829.24 million from Rs 468.71 million in Q1FY26. On a QoQ basis, the profit grew by 60.22% from Rs 3,014.14 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Comprehensive Income: Total comprehensive income for Q1FY27 reached Rs 5,233.66 million, compared to Rs 1,481.98 million in Q1FY26 and Rs 4,900.44 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Earnings Per Share (EPS): Basic EPS for the quarter was Rs 17.11 in Q1FY27, up from Rs 1.66 in Q1FY26 and Rs 10.68 in Q4FY26.</li></ul><p _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">स्टँडअलोन फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c3377174747="">Total Revenue from Operations: Standalone revenue for Q1FY27 was Rs 24,349.93 million, showing a growth of 1.67% YoY from Rs 23,949.28 million in Q1FY26 and an increase of 13.44% QoQ from Rs 21,465.76 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Income: Standalone total income stood at Rs 25,504.04 million in Q1FY27, a growth of 3.50% YoY from Rs 24,642.63 million in Q1FY26 and a 3.91% increase QoQ from Rs 24,544.52 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit After Tax: Standalone profit for the period reached Rs 7,356.37 million in Q1FY27, representing a YoY increase of 122.77% from Rs 3,302.26 million in Q1FY26. The company returned to profitability compared to a loss of Rs 739.02 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Earnings Per Share (EPS): Basic EPS for Q1FY27 was Rs 26.07, compared to Rs 11.70 in Q1FY26 and a negative EPS of Rs 2.62 in Q4FY26.</li></ul><p _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">बिझनेस हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Divestment and Exceptional Item:</strong> During Q1FY27, the Board approved the transfer of the company's Nebulizer brands and intellectual property portfolio to Glenmark Healthcare Limited (a wholly-owned subsidiary) for a cash consideration of Rs 2,230 million. This was recognized as an exceptional gain in the standalone financial results.</li><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">New Labour Codes:</strong> The Group recognized Rs 1,138.91 million in the consolidated results and Rs 1,130.73 million in the standalone results towards employee benefits, following the assessment of the financial implications of the consolidated 'New Labour Codes.'</li><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Dividend Record Date:</strong> The Board set August 31, 2026, as the record date for determining entitlement to the dividend for the financial year ended March 31, 2026.</li><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Committee Reconstitution:</strong> The Board approved the reconstitution of the Risk Management Committee effective August 1, 2026, with Ms. Patricia Andrews appointed as the Chairperson.</li></ul><p><strong>Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals, said:</strong> “We have started FY27 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. India continued to outperform the market, North America delivered robust underlying growth driven by our first-to-market respiratory launches, and Emerging Markets sustained strong momentum, underscoring the strength of our diversified global business.</p><p>The results reinforce the direction of Glenmark’s next phase: strengthening our core businesses while expanding our differentiated specialty and innovation-led platforms. With RYALTRIS® continuing to grow globally, WINLEVI® gaining traction across Europe, and further progress across our oncology portfolio and IGI’s pipeline, we remain focused on disciplined execution, sustainable and profitable growth and creating long-term value.”</p><p><a class="lb" href="/marathi/get-document/post/pdf/5758487/" target="_blank">रिझल्ट PDF</a></p>

• ट्रेंडलाईन
• 4 दिवसांपूर्वी